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Abstract
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disorders. The review reveals strong evidence that methadone maintenance therapy is an economically
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more limited.
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of Opioid Use Disorder Interventions

O

pioid misuse has reached epidemic proportions in the United States. According
to the Centers for Disease Control and Prevention (CDC), in 2014 more than
18,900 people died from an overdose of prescription pain relievers and 10,575
people died from an overdose of heroin, which amounts to 78 Americans dying
from opioid overdose each day. The societal costs associated with opioid misuse
may be as high as $92 billion annually, when health care, labor, and criminal justice
costs are taken into account.
The Administration’s proposed budget for 2017 includes more than $1 billion for
fighting this epidemic, with $920 million to support cooperative agreements with
states to expand access to medication-assisted treatment for opioid use disorders.
While the final budgeted amount will be a product of negotiations with Congress,
there is bipartisan support for significant sums devoted to treatment. Policymakers
now face the key question of how best to spend this money, considering
treatments that are both clinically and cost effective. This Issue Brief discusses
treatments for opioid use disorders and summarizes a new systematic review of
economic evaluations of these interventions.
Upfront: Only 10% of individuals with an opioid use disorder receive any
therapy at all

This Issue Brief discusses
treatments for opioid use
disorders and summarizes a
new systematic review of
economic evaluations of
these interventions.

In a comprehensive literature review, Murphy and Polsky (2016) summarized 49
studies from 2007 through 2015 that included an economic evaluation of an opioid
use disorder intervention. Their findings come with an important caveat, because
only 10% of individuals with an opioid use disorder receive any therapy at all. They
note that the existing economic literature does not answer a simple yet
fundamental question: what is the cost effectiveness of just offering effective
opioid use disorder therapy? It could be that expanding access to different kinds of
treatment brings more people into treatment itself, which may be a cost effective
strategy. This is important to keep in mind because most economic evaluations
have compared alternative therapies, as opposed to evaluating the impact of
making any treatment available to the 90% of patients with an opioid use
disorder who are not currently in treatment.
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Opioid use disorder therapies: What’s effective

Despite higher outpatient
or prescription costs,
pharmacotherapy for
opioid use disorders is
associated with lower

total health care costs.

Effective interventions for opioid use disorders are available and fall into two broad
categories: psychosocial and pharmacological. Psychosocial therapies include
cognitive behavioral therapies, relapse prevention, contingency management
(reinforcing desired behaviors and not reinforcing undesired behaviors), and
motivational enhancement. These therapies can be used by themselves or in
combination with pharmacological therapy.
Pharmacotherapies vary in the degree to which they mimic, or block, the euphoric
effects of opioids. Methadone, a long-acting opioid, activates opioid receptors in
the brain, reducing pain, cravings, and withdrawal symptoms without producing
the full euphoric effects of illicit or prescription opioids. Buprenorphine, a partial
opioid agonist, activates opioid receptors in the brain to a lesser extent, which
minimizes the symptoms of withdrawal and cravings. Maintenance therapy with
methadone or buprenorphine is widely regarded as an effective form of therapy.
Both can also be used to assist with short-term detoxification (medically-supervised
withdrawal). Because they are controlled substances with the potential for abuse,
they are highly regulated. Although not commonly used in the United States,
injectable heroin is another form of pharmacotherapy used in Canada and the
United Kingdom for opiate dependent persons who do not benefit from or cannot
tolerate other opiate replacement treatments.
In contrast, antagonists, such as naloxone and naltrexone, block opioid brain
receptors and have the advantage of being non-narcotic and non-addictive.
Because antagonists block these receptors, they can cause withdrawal symptoms
if taken by an individual physically dependent on opioids. Naloxone is used as a
rescue medication for opioid overdose and is not used alone in the treatment of
opioid dependence. Naloxone is typically combined with buprenorphine to reduce
the likelihood that buprenorphine will be diverted (illicit drugs being used for illicit
purposes) or misused.
Providers have varying abilities to prescribe these pharmacotherapies to treat
opioid use disorder. Buprenorphine is only available by specially trained and
licensed physicians and methadone is only available at specialty clinics. In contrast,
naloxone and naltrexone can be prescribed by any provider who is licensed to
prescribe medications. Additionally, naloxone can be administered by non-medical
personnel and, in some states, is available at pharmacies without a prescription.
Given that policymakers must make decisions on how to allocate scarce resources,
evidence of effectiveness for the treatment of opioid use disorder is not enough—
nor should it be. Economic evaluations can provide evidence to help guide
decisions to allocate public resources efficiently and effectively.
New systematic review finds pharmacotherapy is associated with lower
total health care costs
In their review, Murphy and Polsky found that 30% of the studies focused on
comparing health care use and costs associated with different kinds of treatments.
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Evidence that MMT is
economically

advantageous is strong;
economic evidence on

BMT is limited but
promising.

Overall, they found that in spite of higher outpatient or prescription costs, pharmacotherapy for opioid use disorders is associated with lower total health care costs,
primarily due to lower utilization of high-cost services such as emergency
department (ED) visits and inpatient care.
• A study comparing health plan beneficiaries on MMT with those receiving
non-methadone outpatient treatment found that patients on MMT had
lower health care costs ($7,163 in 2004 USD) than patients with two or more
non-methadone outpatient visits ($14,157) and patients with zero or one
non-methadone outpatient visits ($18,684). The relatively low cost for MMT
patients was due to fewer ED and primary care visits, and fewer inpatient
stays.
Studies comparing different pharmacotherapies show that methadone
maintenance therapy (MMT) patients tend to use more health care resources and
have higher health care costs than patients receiving buprenorphine-naloxone
maintenance therapy (BMT), at least in the short-term (six months).
• One study also showed at six months post treatment, MMT patients were
significantly more expensive than patients being treated with oral naltrexone
and extended-release naltrexone.
• A number of studies compared total health care costs of different BMT
approaches and dosage forms. Patients receiving BMT and psychosocial
therapy had similar costs to those receiving psychosocial therapy only, and
lower costs than those receiving little or no treatment. Other studies found
lower costs associated with buprenorphine-naloxone film versus tablets, and
improved retention in treatment for high-dose versus low-dose buprenorphine-naloxone patients, with no increase in total health care costs.
MMT and BMT are cost effective by US standards for treatments,
although evidence for BMT and naltrexone is more limited
Policymakers are keenly interested in cost offsets, in terms of both health care and
criminal justice-related costs, but also want to know what these scarce resources
are buying in terms of outcomes. Murphy and Polsky reviewed 30 studies that
addressed both the costs and benefits of pharmacotherapy. A key challenge in
translating cost-benefit and cost-effectiveness research for policymakers is how to
standardize outcomes, which can encompass abstinence rates, opioid-free days,
quality of life measures, and benefit-cost ratios. The most frequently used
measure is the quality-adjusted life-year (QALY), which standardizes outcomes
across conditions and treatments. A traditional, though informal, US threshold
for a cost effective intervention has been $50,000 per QALY gained, although
$100,000/QALY has become more accepted recently.
By the $50,000 per QALY standard, multiple studies found that MMT and BMT
would be considered cost effective relative to no pharmacotherapy. However,
other studies calculated much smaller incremental cost-effectiveness gains.
Relative to MMT, extended-release naltrexone had a cost-effectiveness ratio of $72
(in 2014 USD) per opioid free day. Relative to naltrexone, BMT had cost-effectiveness ratios less than $50 (in 2004 USD) for a host of primary outcomes, including
heroin abstinence and days to relapse. But the authors stress that there are no
accepted standards upon which to judge these alternate values.
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MMT may be more cost effective than BMT, but both are better than no
pharmacotherapy

The authors find that
the economic evidence on

BMT and naltrexone
treatments is limited.
However, the results are
promising for BMT, as
well as for contingency
management approaches
and certain therapy

implementation strategies.

Twelve studies focused on MMT, relative to residential therapy or outpatient
non-pharmacological treatments, and two others assessed MMT or BMT relative
to an outpatient non-pharmacological alternative. Several studies compared MMT
with other pharmacological therapies, including injectable heroin and naltrexone.
• Cost-effectiveness and cost-benefit studies comparing MMT and BMT
generally favored MMT, but both are cost effective relative to no treatment
or drug-free treatment. A study of Medicaid patients found that those
receiving either BMT or MMT were 50% less likely to relapse than those
receiving behavioral treatments only. MMT and BMT patients had mean
monthly health care costs that were $184-$191 less than those receiving
behavioral treatment only.
• In one study using modeling to predict cost-effectiveness, extended-release
naltrexone was predicted to be more effective, and also more costly, than
MMT and BMT.
• Overall, abstinence rates were statistically similar for BMT and MMT, but
MMT was less expensive. MMT had better six-month patient retention rates
than BMT, but BMT was more effective in terms of detox rates. MMT was
more cost effective than BMT in terms of opioid-free days.
• In one Canadian study injectable heroin was found to be more cost
effective than MMT, but a UK study found that injectable heroin was slightly
less cost effective than injectable methadone. Of note, the savings
attributed to injectable treatments were associated with the criminal justice
system; injectable forms of both heroin and methadone were cost
ineffective from the National Health Service perspective.
• In studies comparing BMT with no treatment, short-term detoxification, and
naltrexone alone, the results generally favored BMT.
Limited cost-effectiveness evidence on contingency management, other
implementation strategies
Two studies looked at the cost effectiveness of contingency management (CM) with
prizes or vouchers as an add-on to usual treatment for patients with opioid use
disorders. Both used the longest duration of abstinence and the number of
negative urine samples as outcome measures, and calculated incremental cost
effectiveness as $212 per week of abstinence and $156 per negative urine sample.
Murphy and Polsky stress that there are no generally-accepted cost-effectiveness
thresholds for outcomes of this sort. A recent article by the same authors assessed
an internet-delivered CM intervention for substance use disorders, and found that
it was likely cost-effective based on the clinical outcome of abstinence.
A few studies looked at the cost effectiveness of implementation strategies. One
study found unobserved dosing of BMT was more advantageous than observed
dosing, because it was found to be less expensive with no significant differences in
days of heroin use, quality of life, or psychological state. Another study found MMT
programs that were highly concordant with clinical practice guidelines were more
expensive, on average, than less concordant programs but were more effective
with regard to therapy sessions completed, abstinence and quality-of-life scores.
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Conclusion

More research is needed
to better evaluate the
relative cost effectiveness
of these common opioid use
disorder therapies.

The latest systematic review reveals strong evidence that MMT is an economically
advantageous form of treatment for opioid use disorders. The authors find that the
economic evidence on BMT and naltrexone or extended-release naltrexone
treatments is limited. However, the results are promising for BMT, as well as for
contingency management approaches and certain therapy implementation
strategies. Much more research is needed to better evaluate the relative cost
effectiveness of these common opioid use disorder therapies. Evaluations directly
comparing MMT to other pharmacological treatments and analyses assessing
treatment versus no treatment are needed. As policymakers and practitioners
grapple with the fallout of the opioid epidemic, these economic evaluations are
critical in a time where limited resources must be stretched over a large, and
growing population. Researchers, in turn, may need to hear from policymakers
about the cost-effectiveness measures most likely to be useful in the policymaking
process.
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